Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Leinco Technologies
PD-L1 (Atezolizumab) Recombinant Human Monoclonal Antibody (RG7446), Functional Grade
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
LT1750-100MG
产品规格
种属反应
Human
宿主/亚型
Human
/ IgG
Expression System
HEK293 cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
RG7446
抗原
Recombinant extracellular domain-Fc fusion of human PD-L1R
偶联物
形式
Liquid
浓度
≥5.0 mg/mL
纯化类型
Protein A/G
保存液
PBS, pH 7.2-7.4
内含物
no preservative
保存条件
4°C short term, -80°C long term
运输条件
Ambient (domestic); Wet ice (international)
产品详细信息
Specificity: Atezolizumab (RG7446; INN or code name MPDL3280A) activity is directed against PD-L1 (CD274) and B7.1 (CD80).
Endotoxin Level: <1.0 EU/mg as determined by the LAL method.
Purity: ≥95% monomer by analytical SEC.
Preparation: Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage: Functional grade biosimilar antibodies may be stored sterile as received at 2-8C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80C. Avoid Repeated Freeze Thaw Cycles.
靶标信息
Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 receptors (B7-1Rs). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer. Inhibition of PD-L1 by atezolizumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as "immune checkpoint inhibition."
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
